Ono Pharmaceutical Co., Ltd.

Ono Pharmaceuticalco.,ltd.

Hideomi Kijima

Shizuka Ono

Travis Lee Houston

Jun Takeuchi

Melanie Janelle Bevill

Satoshi Itadani

Masato Higashino

Masahiro Ikura

Tetsuya Yasuhiro

Takeshi Nagaura

Courtney S Johnson

Takahiro Nekado

Toshihiko Nishiyama

Stephan D Parent

Takayuki Fujito

Naoko Imura

Shuhei Otani

Compound I as defined, having high S1Preceptor-selective agonist activity on the S1Preceptor, and the crystal forms of Compound I, the salts of Compound I, and the crystal forms of salts thereof are provided as drug substances of pharmaceuticals.

Salt and crystal form of compound having agonistic activity to S1P5 receptor

The present invention relates to an ethane-sulfonate salt of N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, which has an Axl-inhibiting activity and is useful as a prophylactic and/or therapeutic agent for immune diseases, cancer and the like, a crystal thereof, and a pharmaceutical composition thereof.

Ethane-sulfonate salt of quinoline derivative

In order to provide a prophylactic and/or therapeutic agent for Trk-related diseases, the present invention provides a compound which has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and in addition thereto, is excellent in solubility and absorbability against free bases. The compound of the present invention has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and is excellent in solubility and absorbability against free bases, and is therefore useful as a prophylactic and/or therapeutic agent for Trk-related diseases.

Acid-addition salt of Trk-inhibiting compound

Growing community of inventors

Osaka, Japan

Hideomi Kijima